scholarly journals Novel breast cancer risk alleles and endometrial cancer risk

2008 ◽  
Vol 123 (12) ◽  
pp. 2961-2964 ◽  
Author(s):  
Monica McGrath ◽  
I-Min Lee ◽  
Julie Buring ◽  
David J. Hunter ◽  
Immaculata De Vivo
Keyword(s):  
Breast Cancer ◽  
Endometrial Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Endometrial Cancer Risk ◽  
Risk Alleles

Investigation of Triple-Negative Breast Cancer Risk Alleles in An International African-Enriched Cohort

2020 ◽  
Author(s):  
Rachel Martini ◽  
Yalei Chen ◽  
Brittany Jenkins ◽  
Isra Elhussin ◽  
Esther Cheng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Therapeutic Potential ◽  
African Ancestry ◽  
Case Series ◽  
European Ancestry ◽  
Risk Alleles

Abstract Large-scale efforts to identify breast cancer risk alleles have historically taken place among women on European ancestry, with recent efforts to validate these alleles or identify risk alleles applicable to women of African descent. We investigated the effect of previously reported breast cancer and triple-negative breast cancer (TNBC) risk alleles in our African enriched International Center for the Study of Breast Cancer Subtypes (ICSBCS) cohort. Using case-control and nested case-series approaches, we report that the Duffy-null allele (rs2814778) is associated with TNBC risk (OR = 3.814, p = 0.001), specifically among AA individuals, after adjusting for self-indicated race and west African ancestry (OR = 3.368, p = 0.007). We have also validated the protective effect of the minor allele of the ANKLE1 missense variant rs2363956 among AA for TNBC (OR = 0.4204, p = 0.005). We have shown that differential prevalence of the protective allele may reflect a polymorphic function of ANKLE1 in TNBC breast cancer outcomes. These AA specific risk alleles present opportunities for future studies of therapeutic potential that address race-specific differences in BC and TNBC risk and disease outcome.

scholarly journals Breast cancer susceptibility polymorphisms and endometrial cancer risk: a Collaborative Endometrial Cancer Study

2011 ◽  
Vol 32 (12) ◽  
pp. 1862-1866 ◽  
Author(s):  
Catherine S. Healey ◽  
Shahana Ahmed ◽  
Tracy A. O’Mara ◽  
Kaltin Ferguson ◽  
Diether Lambrechts ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Endometrial Cancer ◽  
Cancer Risk ◽  
Cancer Susceptibility ◽  
Breast Cancer Susceptibility ◽  
Endometrial Cancer Risk ◽  
Cancer Study

scholarly journals Tamoxifen Therapy for Breast Cancer and Endometrial Cancer Risk

1999 ◽  
Vol 91 (19) ◽  
pp. 1654-1662 ◽  
Author(s):  
L. Bernstein ◽  
D. Deapen ◽  
J. R. Cerhan ◽  
S. M. Schwartz ◽  
J. Liff ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Endometrial Cancer ◽  
Cancer Risk ◽  
Tamoxifen Therapy ◽  
Endometrial Cancer Risk

IV.3 The combined effects of ERT, obesity and tamoxifen therapy for breast cancer on endometrial cancer risk

1998 ◽  
Vol 34 ◽  
pp. S46 ◽  
Author(s):  
L. Bernstein ◽  
J. Cerhan ◽  
S. Schwartz ◽  
J. Liff ◽  
J. Perlman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Endometrial Cancer ◽  
Cancer Risk ◽  
Tamoxifen Therapy ◽  
Combined Effects ◽  
Endometrial Cancer Risk

scholarly journals Impact of Raloxifene or Tamoxifen Use on Endometrial Cancer Risk: A Population-Based Case-Control Study

2008 ◽  
Vol 26 (25) ◽  
pp. 4151-4159 ◽  
Author(s):  
Angela DeMichele ◽  
Andrea B. Troxel ◽  
Jesse A. Berlin ◽  
Anita L. Weber ◽  
Greta R. Bunin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Endometrial Cancer ◽  
General Population ◽  
Cancer Risk ◽  
African American Women ◽  
Case Control Study ◽  
Case Control ◽  
Low Grade ◽  
Endometrial Cancer Risk ◽  
Control Study

Purpose Raloxifene reduces breast cancer risk in women with osteoporosis, and both tamoxifen and raloxifene prevent breast cancer in high-risk women. However, in vitro, raloxifene does not share the pro-estrogenic effects of tamoxifen on the endometrium. Randomized trials of these agents have provided limited information about endometrial cancer risk in the general population. We sought to compare endometrial cancer risks associated with raloxifene, tamoxifen, and nonusers of a selective estrogen receptor modulator (SERM) in the general population and characterize the endometrial tumors occurring in these groups. Methods We performed a case-control study of white and African American women age 50 to 79 years in the Philadelphia area. Patients were diagnosed with endometrial cancer between July 1999 and June 2002. Controls were identified through random-digit dialing. Results We analyzed 547 cases and 1,410 controls. Among cases, 3.3% had taken raloxifene; 6.2% had taken tamoxifen. Among controls, 6.6% had taken raloxifene; 2.4% had taken tamoxifen. After adjustment for other risk factors, the odds of endometrial cancer among raloxifene users was 50% that of nonusers (odds ratio [OR] = 0.50; 95% CI, 0.29 to 0.85), whereas tamoxifen users had three times the odds of developing endometrial cancer compared with raloxifene users (OR = 3.0; 95% CI, 1.3 to 6.9). Endometrial tumors in raloxifene users had a more favorable histologic profile and were predominantly International Federation of Gynecology and Obstetrics stage I and low grade. Conclusion Raloxifene users had significantly lower odds of endometrial cancer compared with both tamoxifen users and SERM nonusers, suggesting a role for raloxifene in endometrial cancer prevention and individualization of SERM therapy.

Sign in / Sign up

Export Citation Format

Share Document